The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

President Joe Biden, proposed a rule in November that would have extended coverage of drugs like Zepbound and Wegovy. CMS did not offer an explanation Friday for its decision, and federal ...